{"nctId":"NCT00433966","briefTitle":"Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction","startDateStruct":{"date":"2005-03"},"conditions":["Myocardial Infarction"],"count":3602,"armGroups":[{"label":"Pharmacology Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bivalirudin","Drug: Unfractionated heparin"]},{"label":"Stent Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Bare metal stent","Device: Paclitaxel-eluting stent"]}],"interventions":[{"name":"Bivalirudin","otherNames":["Angiomax"]},{"name":"Unfractionated heparin","otherNames":["Heparin Sodium"]},{"name":"Bare metal stent","otherNames":["EXPRESS2™"]},{"name":"Paclitaxel-eluting stent","otherNames":["TAXUS™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have clinical symptoms consistent with AMI (e.g., angina or anginal equivalent)lasting \\>20 minutes but \\<12 hours in duration;\n* ST-segment elevation of \\>1 mm in \\>2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \\>1 mm in \\>2 contiguous anterior leads;\n* The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent.\n\nExclusion Criteria:\n\n* The patient has a known hypersensitivity or contraindication to any of the following medications:\n\n  * Heparin, pork or pork products\n  * Both abciximab and eptifibatide\n  * Aspirin\n  * Both Clopidogrel and Ticlopidine\n  * Bivalirudin\n  * Paclitaxel or Taxol\n  * The polymer components of the TAXUS™ stent (SIBS)\n  * Stainless steel and/or\n  * Contrast media;\n* Prior administration of thrombolytic therapy, bivalirudin, GP IIb/IIIa inhibitors, low molecular weight heparin or fondaparinux for this admission. Patients receiving prior unfractionated heparin may be enrolled, and treated per randomization;\n* Current use of coumadin;\n* Systemic (intravenous) Paclitaxel or Taxol use within 12 months;\n* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plans to become pregnant any time after enrollment into this study;\n* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions;\n* History of intra-cerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke;\n* Stroke or transient ischemic attack within the past 6 months, or any permanent residual neurologic defect;\n* Gastrointestinal or genitourinary bleeding within the last 2 months, or major surgery within six weeks;\n* Recent history or known current platelet count \\<100,000 cells/mm3 or Hgb \\<10 g/dL;\n* Extensive peripheral vascular disease, such that emergent angiography and intervention in the opinion of the investigator is likely to be difficult or complicated;\n* An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first six months post enrollment;\n* Non-cardiac co-morbid conditions are present with life expectancy \\<1 year or that may result in protocol non-compliance;\n* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period;\n* Previous enrollment in this trial;\n* Patients who underwent coronary stent implantation within the past 30 days.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events","description":"Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"218","spread":null}]}]}]},{"type":"PRIMARY","title":"Stent Arm - Ischemic Target Lesion Revascularization","description":"Number of Participants With Ischemic Target Lesion Revascularization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"PRIMARY","title":"Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis","description":"Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacology Arm - Major Adverse Cardiovascular Events","description":"Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding","description":"Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]}]},{"type":"SECONDARY","title":"Stent Arm - Segment Binary Angiographic Restenosis","description":"Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacology Arm - Major Adverse Cardiovascular Events","description":"Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"377","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":397,"n":1800},"commonTop":["Global Use of Strategies to Open Occluded Arteries Mild Bleeding","Thrombolysis in Myocardial Infarction Minor Bleeding"]}}}